Zhejiang University index predicts metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus patients
Abstract
The Zhejiang University (ZJU) index, which combines body mass index, fasting blood glucose, triglyceride level and alanine aminotransferase/aspartate aminotransferase ratio, can be used to predict metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM). The ZJU index of 38.87 has been identified as the key threshold for diagnosing MASLD. The new model for predicting MASLD in T2DM based on ZJU index shows high diagnostic value. While the study is methodologically robust and offers a valuable clinical tool, it is limited by its cross-sectional design, inpatient cohort bias, unadjusted pharmacotherapy effects, and reliance on ultrasound for MASLD diagnosis. Future validation in outpatient settings, incorporating medication data and advanced fibrosis assessment, is crucial to translate this cost-effective biomarker into wide practice.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.